Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University, shared an article by John W K Chia, et al. on LinkedIn:
“Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial.”
, Professor of Medicine Emeritus at Brown University, reshared the post, adding:
“Disappointing information. But why such a high dose of ASA? That’s out of line with recent studies.
Those who regularly took aspirin had a colorectal cancer 10-year cumulative incidence of 1.98 percent, compared with 2.95 percent among those who did not take aspirin.
“Based on prior studies, the best evidence supports daily low-dose (81 mg) aspirin for prevention.”
Maybe another study using lower doses eg. 81mg daily vs 81mg three times a week might be worthwhile considering.
These doses are more also more effective at preventing cardiovascular issues than higher doses.”
Authors: John W K Chia, et al.
